Atrasentan is an endothelin A receptor antagonist used in clinical research to reduce proteinuria and slow the progression of kidney disease, particularly in primary IgA nephropathy. In pharmaceutical… Read more
Atrasentan is an endothelin A receptor antagonist used in clinical research to reduce proteinuria and slow the progression of kidney disease, particularly in primary IgA nephropathy. In pharmaceutical analysis, identifying and quantifying this compound requires a comprehensive set of analytical tools, including reference standards for the API, known impurities, and stereoisomers. Laboratories utilize these high-purity reference materials for rigorous impurity profiling and method validation, ensuring compliance with established quality control specifications. Additionally, stable isotope-labelled versions of Atrasentan are essential for supporting pharmacokinetic studies, where they serve as internal standards for mass spectrometry-based quantification. By providing access to these metabolites and related degradation products, researchers can effectively monitor compound stability and verify the accuracy of analytical methods throughout the drug development lifecycle.